Literature DB >> 20135354

Pan-azole-resistant Candida guilliermondii from a leukemia patient's silent funguria.

Vincenzo Savini, Chiara Catavitello, Ilaria Di Marzio, Gioviana Masciarelli, Daniela Astolfi, Andrea Balbinot, Azaira Bianco, Arianna Pompilio, Giovanni Di Bonaventura, Claudio D'Amario, Domenico D'Antonio.   

Abstract

Isolation of Candida non-albicans yeasts as commensals or pathogens from hospitalised hosts is acquiring increasing importance, due to the frequent drug resistance expressed by such organisms.Particularly, the recover of antifungal resistant C. guilliermondii is of worrisome concern, even if recovered as a saprophyte, since commensal yeasts may behave as reservoirs for resistance elements;furthermore, they may enter the bloodstream after chemotherapy-related mucosal damage has developed,thus causing life-threatening and difficult-to-treat fungemias. This communication deals with the unusual isolation of a pan-azole resistant C. guilliermondii strain from a leukaemic patient with silent candiduria and emphasizes the importance of monitoring less recurring species within the nosocomial setting to better understand fungal epidemiology within the wards and face the spread of resistance determinants. Also, we highlight the controversial significance of silent candiduria, clinical relevance of which should be investigated case by case, to exclude and/or prevent candiduria as well as renal impairment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20135354     DOI: 10.1007/s11046-010-9278-5

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  10 in total

1.  Candida colonization in intensive care unit patients' urine.

Authors:  Xisto Sena Passos; Werther Souza Sales; Patrícia Jackeline Maciel; Carolina Rodrigues Costa; Karla Carvalho Miranda; Janine de Aquino Lemos; Miranildes de Abreu Batista; Maria do Rosário Rodrigues Silva
Journal:  Mem Inst Oswaldo Cruz       Date:  2006-01-20       Impact factor: 2.743

2.  Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Serena Tomassetti; Agnese Della Vittoria; Daniela Arzeni; Esther Manso; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.

Authors:  M A Pfaller; D J Diekema; M Mendez; C Kibbler; P Erzsebet; S-C Chang; D L Gibbs; V A Newell
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

4.  Candida guilliermondii fungemia in patients with hematologic malignancies.

Authors:  Corrado Girmenia; Giampaolo Pizzarelli; Francesco Cristini; Francesco Barchiesi; Elisabetta Spreghini; Giorgio Scalise; Pietro Martino
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

Review 5.  In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

Authors:  Ana Espinel-Ingroff
Journal:  Rev Iberoam Micol       Date:  2003-12       Impact factor: 1.044

6.  In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method.

Authors:  C Girmenia; G Pizzarelli; D D'Antonio; F Cristini; P Martino
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

7.  Recent experience with fungaemia: change in species distribution and azole resistance.

Authors:  Arunaloke Chakrabarti; Shiv Sekhar Chatterjee; K L N Rao; M M Zameer; M R Shivaprakash; Sunit Singhi; Rajinder Singh; Shubhash Chandra Varma
Journal:  Scand J Infect Dis       Date:  2009

8.  In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis; R N Jones
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

Review 9.  Antifungal prophylaxis with azole derivatives.

Authors:  E Castagnola; M Machetti; B Bucci; C Viscoli
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

Review 10.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Authors:  A Espinel-Ingroff; K Boyle; D J Sheehan
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

  10 in total
  6 in total

1.  Candida fermentati as a cause of persistent fungemia in a preterm neonate successfully treated by combination therapy with amphotericin B and caspofungin.

Authors:  Noura Al-Sweih; Suhail Ahmad; Leena Joseph; Seema Khan; Sandhya Vayalil; Rachel Chandy; Ziauddin Khan
Journal:  J Clin Microbiol       Date:  2015-01-07       Impact factor: 5.948

2.  Candida guilliermondii: biotechnological applications, perspectives for biological control, emerging clinical importance and recent advances in genetics.

Authors:  Nicolas Papon; Vincenzo Savini; Arnaud Lanoue; Andrew J Simkin; Joël Crèche; Nathalie Giglioli-Guivarc'h; Marc Clastre; Vincent Courdavault; Andriy A Sibirny
Journal:  Curr Genet       Date:  2013-04-25       Impact factor: 3.886

3.  Identification and Antifungal Susceptibility Profile of Candida guilliermondii and Candida fermentati from a Multicenter Study in China.

Authors:  Jing-Wei Cheng; Shu-Ying Yu; Meng Xiao; He Wang; Timothy Kudinha; Fanrong Kong; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2016-06-01       Impact factor: 5.948

4.  Candiduria in haematologic malignancy patients without a urinary catheter: nothing more than a frailty marker?

Authors:  Sarah P Georgiadou; Jeffrey Tarrand; Nikolaos V Sipsas; Dimitrios P Kontoyiannis
Journal:  Mycoses       Date:  2012-11-22       Impact factor: 4.377

5.  Molecular epidemiology and azole resistance mechanism study of Candida guilliermondii from a Chinese surveillance system.

Authors:  Jing-Wei Cheng; Kang Liao; Timothy Kudinha; Shu-Ying Yu; Meng Xiao; He Wang; Fanrong Kong; Ying-Chun Xu
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

6.  Fungemia caused by Candida species in a children's public hospital in the city of São Paulo, Brazil: study in the period 2007-2010.

Authors:  Vanessa Kummer Perinazzo Oliveira; Luciana da Silva Ruiz; Nélio Alessandro Jesus Oliveira; Débora Moreira; Rosane Christine Hahn; Analy Salles de Azevedo Melo; Angela Satie Nishikaku; Claudete Rodrigues Paula
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jul-Aug       Impact factor: 1.846

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.